Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
Related Questions
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
In a patient with severe TR, when is the best time to start thinking about T-TEER?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
What factors would influence your decision to use or avoid heparin bridging in patients with mechanical heart valves resuming anticoagulation after intracerebral hemorrhage?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
What is your approach to the management of severe tricuspid regurgitation secondary to endocarditis with the presence of an RV pacemaker lead in place?
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
